News >

T-Cell Fuel Source, Chemotherapy Exposure Reduce Potential to Develop CAR-T Therapy

Jason Harris
Published: Thursday, Mar 15, 2018

 David M. Barrett, MD, PhD

David M. Barrett, MD, PhD
Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor (CAR) T-cell therapy.

Oxygen consumption rate (OCR) analysis revealed a poor spare respiratory capacity (SRC) in the T cell samples that go on to perform poorly as CAR T cells. Nanostring RNA profiling of metabolic pathways showed that the poor performing samples were more likely to use glycolysis as a fuel source, rather than fatty acids.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication